President’s Message

Dear ALTG Colleagues,

It’s already May and we’re focused on key targets to progress our clinical trial portfolio, extending the reach of our educational programs, and growing our reputation within the lung and thoracic cancer space.

2017 was an exciting year of trial activity; BR.34 study (a randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in NSCLC) and the OSCILLATE study (Alternating osimertinib and gefitinib in patients with EGFR T790M positive NSCLC) are well into patient enrolment. The NIVORAD study (a trial combining nivolumab with local, palliative Stereotactic Ablative Body Radiotherapy (SABR) in patients with advanced NSCLC) and PEARL study (a study of early referral to palliative care for patients with advanced thoracic cancer) are also actively enrolling patients followed by start-up activities for the ILLUMINATE study (a trial of durvalumab and tremelimumab with chemotherapy in non-squamous non-small cell lung cancer (NSCLC)) and the STIMULI study (a randomised trial of nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy). Over 110 patients were enrolled in ALTG trials in 2017; a significant increase over 2016.

Applications for our 4th Preceptorship in Lung Cancer is now open on the ALTG website so please highlight this excellent learning and mentoring opportunity to your early career researchers and consultant colleagues. The objective of the program is to critically appraise and evaluate key evidence supporting the evolution of clinical practice of lung cancer diagnosis and management, in early and advanced settings, incorporating supportive care, modern treatments and technologies, including modern molecular technology and immune-profiling for selection of targeted therapies and immunotherapy. The program will also include a segment dedicated to determining the clinical question and how to develop that question into a concept. Top concepts from the Preceptorship will be invited to present their concepts to the Scientific Advisory Committee (SAC) at the next meeting. The Preceptorship date is 17-18 August, in Melbourne. Travel grants will be provided to successful applicants. Registration is filling quickly.

The 2018 ALTG Symposium will be held in Sydney and we hope to enter into a two year contract with the venue. Since the Australian Lung Cancer Conference (ALCC) was held this year, the format of the ALTG Symposium will change slightly towards an Academic Scientific Meeting (ASM).  The purpose of this change is to insure delegates are presented with a different perspective of current, evidence based research and transitioning that evidence into practical applications in the clinic. Our annual ALTG Members’ Meeting will precede the ASM followed by welcome reception on the Friday night so mark 5-6 October in your diaries for a trip to Sydney.


Assoc. Professor Nick Pavlakis BSc MBBS MMed (Clin. Epi) PhD FRACP

President, Australasian Lung Cancer Trials Group (ALTG)